|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
Datamonitor, April 2005, Pages: 124
Introduction
The asthma, COPD and allergic rhinitis global market was $25.5 billion in 2004, with five brands selling over $1.0 billion. While a number of moderately successful launches are expected within the next five years, companies are seeking novel combination therapies to create the next generation of blockbuster drugs.
Evaluation of over 75 drugs in clinical development for asthma, COPD, and allergic rhinitis, including launch forecasts
Opinion leader insight into early stage therapies and treatment strategies
Forecasts of key late-stage therapies: Alvesco (ciclesonide), Daxas (roflumilast), Xolair (omalizumab), Xopenex (levalbuterol)
Forecasted sales of the respiratory market in the next 10 years, exploring the potential impact of early phase therapies
Report Highlights
Inhaled corticosteroid/long-acting b2-agonist fixed combinations will remain the leading asthma/COPD class in 2015, almost exclusively represented by sales of GSKs 'Super Advair', with its once-daily profile setting the new gold standard.
Merck may invigorate the oral asthma market through the development of a Singulair/ prostaglandin-D2 combination product, while monoclonal antibodies will be the fastest growing asthma class, with therapies that are effective in non-atopic asthma having a $1.0 billion sales opportunity.
Novel, long-acting, dual-action bronchodilator combinations will expand the COPD market from 2012, with novel triple combinations on the horizon. Altana/Pfizers Daxas will achieve peak sales of $750 million by 2010, although 12-month data and combination trials with Spiriva will be key to success.
Reasons to Purchase
Understand unmet needs in the respiratory market, and how late-stage compounds address these needs
Identify potential licensing opportunities for respiratory market entry or portfolio expansion
Benchmark key late-stage asthma and COPD compounds against market leaders
Customers who bought this item also bought
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Asthma And COPD - Get Smart
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Commercial and Pipeline Insight: Allergic Rhinitis
Asthma & COPD Therapeutics
Forecast Insight: Asthma/COPD - Little Long-term Future for Long-acting Single-agent Inhalers?
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Commercial Insight: Asthma and COPD - Control is the Goal
|
|
|
|
